Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01092611 · ClinicalTrials.gov registry record · Phase 1

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

A Phase 1 study of AIDS, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 1
Development phase
190
Enrollment target
20
Study locations

NCT01092611 is a Phase 1 study of AIDS that has completed, run by GlaxoSmithKline. The registered enrollment target is 190 participants, below the 1,567-participant average among 13 other AIDS trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01092611, a Phase 1 study of AIDS, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 1
Development phase
190 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this long-term follow-up study is to assess the long-term health status of HIV-infected subjects who previously participated in GSK-sponsored trials evaluating the investigational HIV vaccine 732462. This study will provide additional data concerning the long-term benefits/risks associated with vaccination. No vaccine will be administered during the study period. Vaccines were administered during the primary studies.

Conditions Studied

AIDS

Interventions

  • PROCEDURE Blood collection
  • BIOLOGICAL GSK HIV vaccine 732462

Study Locations (20)

Other

  • GSK Investigational Site - Bobigny
  • GSK Investigational Site - Créteil
  • GSK Investigational Site - Nantes
  • GSK Investigational Site - Paris
  • GSK Investigational Site - Paris
  • GSK Investigational Site - Paris
  • GSK Investigational Site - Paris
  • GSK Investigational Site - Paris
  • GSK Investigational Site - Paris

Florida

  • GSK Investigational Site - Fort Lauderdale
  • GSK Investigational Site - Orlando

Pennsylvania

  • GSK Investigational Site - Philadelphia
  • GSK Investigational Site - Philadelphia

California

  • GSK Investigational Site - Bakersfield

Nebraska

  • GSK Investigational Site - Omaha

New Jersey

  • GSK Investigational Site - Camden

Ohio

  • GSK Investigational Site - Columbus

Texas

  • GSK Investigational Site - Dallas

Trial Details

FieldValue
Enrollment Target 190 participants
Start Date 2010-03-22
Est. Completion 2014-05-19
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01092611

The ClinicalTrials.gov registry entry for NCT01092611 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,567-participant average among 13 other AIDS trials with a reported enrollment target (88% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with AIDS appearing as the primary indexed condition, and to 2 interventions - of which Blood collection is the first listed.

NCT01092611 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Florida, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01092611 about?

NCT01092611 is a clinical study titled "Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine". The purpose of this long-term follow-up study is to assess the long-term health status of HIV-infected subjects who previously participated in GSK-sponsored trials evaluating the investigational HIV vaccine 732462. This study will provide additional data concerning the long-term benefits/risks assoc...

What is the current status of trial NCT01092611?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 190 participants. The study started on 2010-03-22. Estimated completion is 2014-05-19.

What conditions does trial NCT01092611 study?

This clinical trial studies the following conditions: AIDS.

What interventions are being tested in trial NCT01092611?

The interventions under investigation include: Blood collection (PROCEDURE), GSK HIV vaccine 732462 (BIOLOGICAL).

Who is sponsoring clinical trial NCT01092611?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01092611 being conducted?

This trial has 20 study locations across California, Florida, Nebraska, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for AIDS

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

AIDS

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.